Explore the vast range of titles available.

Objectives The objectives of this narrative review are to summarize the current state of AI applications in neuroimaging for early Alzheimer's disease (AD) prediction and to highlight the potential of AI techniques in improving early AD diagnosis, prognosis, and management. Methods We conducted a narrative review of studies using AI techniques applied to neuroimaging data for early AD prediction. We examined single-modality studies using structural MRI and PET imaging, as well as multi-modality studies integrating multiple neuroimaging techniques and biomarkers. Furthermore, they reviewed longitudinal studies that model AD progression and identify individuals at risk of rapid decline. Results Single-modality studies using structural MRI and PET imaging have demonstrated high accuracy in classifying AD and predicting progression from mild cognitive impairment (MCI) to AD. Multi-modality studies, integrating multiple neuroimaging techniques and biomarkers, have shown improved performance and robustness compared to single-modality approaches. Longitudinal studies have highlighted the value of AI in modeling AD progression and identifying individuals at risk of rapid decline. However, challenges remain in data standardization, model interpretability, generalizability, clinical integration, and ethical considerations. Conclusion AI techniques applied to neuroimaging data have the potential to improve early AD diagnosis, prognosis, and management. Addressing challenges related to data standardization, model interpretability, generalizability, clinical integration, and ethical considerations is crucial for realizing the full potential of AI in AD research and clinical practice. Collaborative efforts among researchers, clinicians, and regulatory agencies are needed to develop reliable, robust, and ethical AI tools that can benefit AD patients and society.

Improved prediction of progression to Alzheimer's Disease (AD) among older individuals with mild cognitive impairment (MCI) is of high clinical and societal importance. We recently developed a polygenic hazard score (PHS) that predicted age of AD onset above and beyond . Here, we used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to further explore the potential clinical utility of PHS for predicting AD development in older adults with MCI. We examined the predictive value of PHS alone and in combination with baseline structural magnetic resonance imaging (MRI) data on performance on the Mini-Mental State Exam (MMSE). In survival analyses, PHS significantly predicted time to progression from MCI to AD over 120 months ( = 1.07e-5), and PHS was significantly more predictive than alone ( = 0.015). Combining PHS with baseline brain atrophy score and/or MMSE score significantly improved prediction compared to models without PHS (three-factor model = 4.28e-17). Prediction model accuracies, sensitivities and area under the curve were also improved by including PHS in the model, compared to only using atrophy score and MMSE. Further, using linear mixed-effect modeling, PHS improved the prediction of change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score and MMSE over 36 months in patients with MCI at baseline, beyond both and baseline levels of brain atrophy. These results illustrate the potential clinical utility of PHS for assessment of risk for AD progression among individuals with MCI both alone, or in conjunction with clinical measures of prodromal disease including measures of cognitive function and regional brain atrophy.

Because Alzheimer's disease (AD) has significant heterogeneity in encephalatrophy and clinical manifestations, AD research faces two critical challenges: eliminating the impact of natural aging and extracting valuable clinical data for patients with AD. This study attempted to address these challenges by developing a novel machine-learning model called tensorized contrastive principal component analysis (T-cPCA). The objectives of this study were to predict AD progression and identify clinical subtypes while minimizing the influence of natural aging. We leveraged a clinical variable space of 872 features, including almost all AD clinical examinations, which is the most comprehensive AD feature description in current research. T-cPCA yielded the highest accuracy in predicting AD progression by effectively minimizing the confounding effects of natural aging. The representative features and pathogenic circuits of the four primary AD clinical subtypes were discovered. Confirmed by clinical doctors in Tangdu Hospital, the plaques (18F-AV45) distribution of typical patients in the four clinical subtypes are consistent with representative brain regions found in four AD subtypes, which further offers novel insights into the underlying mechanisms of AD pathogenesis.

In the era of digitization, online digital advertising is one of the best techniques for modern marketing. This makes advertisers rely heavily on accurate user interest and behavior modelling to deliver precise advertisement impressions and increase click-through rates. The classic approach to model user interests has often required the use of predefined feature sets which are typically stagnant and not representative of temporal changes and trends in user behavior. While recent advances in deep learning offer potential solutions to these obstacles, many existing approaches fail to address the sequential nature of user interactions. In this paper, we propose an optimized Bi-Directional Long Short-Term Memory (Bi-LSTM) based user interest modeling approach together with an Updated version of Parrot Optimizer (UPO) to enhance performance. It treats the user activity as a temporal sequence which well fits the changing nature of user interest and preferences over time. The proposed approach is evaluated on two important tasks: predicting the probability that a user will click on an ad and predicting the probability that a user will click on a particular type of ad campaign. Simulation results demonstrate that the proposed method provides superior results than the static set-based approaches and achieves significant improvements on both user ad responses predictions and user ad clicks at the campaign level. The research also enhances the efficiency of user interest modeling with significant implications for online advertising, recommendation systems, and personalized marketing.

ADHD classification has traditionally relied on accelerometer-derived tabular features, which summarise static activity but fail to capture spatial-temporal patterns, potentially limiting model performance. We developed a multimodal deep learning framework that transforms raw accelerometer signals into images and integrates them with clinical tabular data, enabling the joint exploration of dynamic activity patterns and static clinical characteristics. Data were collected from children aged 7–13 years, including accelerometer recordings from Apple Watches and clinical measures from standardised questionnaires. Deep learning models for image feature extraction and multiple fusion strategies were evaluated to identify the most effective representation and integration method. Our analyses indicated that combining activity images with clinical variables facilitated the classification of ADHD, with the ViT-BiLSTM model using cross-attention fusion achieving the highest performance. These findings suggest that multimodal learning can become a robust approach to ADHD classification by leveraging complementary information from activity dynamics and clinical data. Our framework and code will be made publicly available to support reproducibility and future research.

Background: Automated tools for characterizing dementia risk have the potential to aid in the diagnosis, prognosis, and treatment of Alzheimer’s Disease (AD). Here, we examined a novel machine learning-based brain atrophy marker, the AD-resemblance atrophy index (AD-RAI), to assess its test-retest reliability and further validate its use in disease classification and prediction. Methods: Age- and sex-matched 44 probable AD (Age: 69.13  7.13; MMSE: 27-30) and 22 non-demented control (Age: 69.38  7.21; MMSE: 27-30) participants were obtained from the Minimal Interval Resonance Imaging in Alzheimer's Disease (MIRIAD) dataset. After data exclusion, we selected serial T1-weighted images (n = 679) from these participants across over a two-year period, including 179 pairs of scans acquired on the same day and 40 pairs of scans acquired at two-week intervals. All images were automatically processed with AccuBrain® to calculate the AD-RAI. Its same-day repeatability and two-week reproducibility were first assessed. The discriminative performance of AD-RAI was evaluated using the receiver operating characteristic curve, where DeLong’s test was used to evaluate its performance against quantitative medial temporal lobe atrophy (QMTA) and hippocampal volume adjusted by intracranial volume (ICV)-proportions and ICV-residuals methods, respectively (HVR and HRV). Linear mixed-effects modelling was used to investigate longitudinal trajectories of AD-RAI and baseline AD-RAI prediction of cognitive decline. Finally, the longitudinal associations between AD-RAI and MMSE scores were assessed. Results: AD-RAI had excellent same-day repeatability and excellent two-week reproducibility. AD-RAI’s AUC (99.8%; 95%CI = [99.3%, 100%]) was equivalent to that of QMTA (96.8%; 95%CI = [92.9%, 100%]), and better than that of HVR (86.8%; 95%CI = [78.2%, 95.4%]) or HRV (90.3%; 95%CI = [83.0%, 97.6%]). While baseline AD-RAI was significantly higher in the AD group, it did not show detectable changes over 2 years. Baseline AD-RAI was negatively associated with MMSE scores and the rate of the change in MMSE scores over time. A negative longitudinal association was also found between AD-RAI values and the MMSE scores among AD patients. Conclusions: The AD-RAI represents a potential biomarker that may support AD diagnosis and be used to predict the rate of future cognitive decline in AD patients.

Tumor necrosis factor-α (TNF-α) is a drug target in rheumatoid arthritis and several other auto-immune disorders. TNF-α binds with TNF receptors (TNFR), located on the surface of several immunological cells to exert its effect. Hence, the use of inhibitors that can hinder the complex formation of TNF-α/TNFR can be of medicinal significance. In this study, multiple chem-informatics approaches, including descriptor-based screening, 2D-similarity searching, and pharmacophore modelling were applied to screen new TNF-α inhibitors. Subsequently, multiple-docking protocols were used, and four-fold post-docking results were analyzed by consensus approach. After structure-based virtual screening, seventeen compounds were mutually ranked in top-ranked position by all the docking programs. Those identified hits target TNF-α dimer and effectively block TNF-α/TNFR interface. The predicted pharmacokinetics and physiological properties of the selected hits revealed that, out of seventeen, seven compounds (4, 5, 10, 11, 13–15) possessed excellent ADMET profile. These seven compounds plus three more molecules (7, 8 and 9) were chosen for molecular dynamics simulation studies to probe into ligand-induced structural and dynamic behavior of TNF-α, followed by ligand-TNF-α binding free energy calculation using MM-PBSA. The MM-PBSA calculations revealed that compounds 4, 5, 7 and 9 possess highest affinity for TNF-α; 8, 11, 13–15 exhibited moderate affinities, while compound 10 showed weaker binding affinity with TNF-α. This study provides valuable insights to design more potent and selective inhibitors of TNF-α, that will help to treat inflammatory disorders.

Today, the world has experienced a new trend with regard to data system management, traditional database management tools have become outdated and they will no longer be able to process the mass of data generated by different systems, that's why big data is there to process this mass of data to bring out crucial information hidden in this data, and without big data technologies the treatment is very difficult to manage; among the domains that uses big data technologies is vehicular ad-hoc network to manage their voluminous data. In this article, we establish in the first step a method that allow to detect anomalies or accidents within the road and compute the time spent in each road section in real time, which permit us to obtain a database having the estimated time spent in all sections in real time, this will serve us to send to the vehicles the right estimated time of arrival all along their journey and the optimal route to attain their destination. This database is useful to utilize it like inputs for machine learning to predict the places and times where the probability of accidents is higher. The experimental results prove that our method permits us to avoid congestions and apportion the load of vehicles in all roads effectively, also it contributes to road safety.